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Arterial hypertension, alone or in combination with ischemic heart disease, precedes the
development of heart failure. The Framingham study demonstrated that hypertension was the
major risk factor in the development of heart failure. Arterial hypertension is not a sole factor
contributing to the development of heart failure. The syndrome of heart failure is a
consequence of multiple systemic responses and the development of heart failure is a complex
and progressive process associated with cardiovascular disease resulting from risk factors:
hypertension, obesity, smoking and dyslipidaemia. Arterial hypertension is the main precursor
of left ventricular hypertrophy. Initially, this process causes diastolic dysfunction in the early
stages of primary hypertension. Systolic dysfunction is rarely observed in those subjects. Left
ventricular hypertrophy is also an important risk factor for myocardial infarction and
ventricular arrhythmias. Asymptomatic systolic and diastolic left ventricular dysfunction may
both progress to overt HF
The primary prevention of heart failure patients should be based upon strategies providing
tight and sustained blood pressure control. This therapy should include an agent that inhibits
the renin–angiotensin–aldosterone system. Treatment of arterial hypertension in patients with
HF must take into account the prevalent type of cardiac dysfunction—diastolic or systolic.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Arterial hypertension is a risk factor for the development of
chronic heart failure (CHF) and leads to the development of
left ventricular hypertrophy. Arterial hypertension is a risk
factor for the development of coronary heart disease (CHD).
The relative risk of CHF among patients with arterial hyper-
tension, compared to general population, was estimated to be
1.4 in an analysis from the First National Health and Nutri-
tion Examination Survey [1]. In addition, patients with CHF
may present with hypertension. In the general population,
prognosis is poorer for hypertensive than for normotensive
individuals. In contrast to the pattern seen in the general
population, higher blood pressure prior to treatment is a
predictor of better survival in patients with CHF.
Arterial hypertension and CHF are both major public health
problems in the developed countries. Arterial hypertension
is the most important modiﬁable risk factor for CHF [2].
The incidence, prevalence of and overall mortality from CHF
has been increasing in recent decades, while the incidence of
and mortality from CHD and stroke have been continuously
declining.
Arterial hypertension is a disease of the cardiovascular
system that primarily manifests as the chronic presence of a
resting arterial pressure greater than 140/90 mmHg andmay be
associated with the development of myocardial disease,
i.e. cardiomyopathy. CHF is a clinical syndrome that manifests
late in the course of cardiomyopathy. Hypertensive heart
disease and hypertensive cardiomyopathy as the ultimate
cause of heart failure associated with arterial hypertension, is
due to the increased workload of the heart. Arterial hyperten-
sion seldom exists without other risk factors and comorbid
conditions. In addition to gender, those factors include geno-
type, body size, coronary artery disease, diabetes mellitus,
obesity and alcohol intake. Arterial hypertension is an impor-
tant factor in the production of a pluricausal cardiomyopathy.2. Epidemiology
The Framingham heart study showed that arterial hyperten-
sion, alone or in combination with CHD, preceded the devel-
opment of CHF in 70% of both men and women [3,4]. Arterial
hypertension was the most frequent cause of CHF in the 30 to
62-year age group. CHF occurred six times more frequently
among hypertensive than among normotensive subjects.
The progression from arterial hypertension alone to hyper-
tension with CHF was reported for participants in the original
Framingham Heart Study and the Framingham Offspring
Study initiated in 1970. The risk of CHF in hypertensive was
twice as high in men and free times as high in women,
compared with normotensive subjects, when adjusted for
age and risk factors for CHF [5]. The ﬁve year survival rate
for hypertensive CHF was 24% for men and 31% for women.
The risk for CHF in hypertensive subjects depends on hyper-
tension grade, i.e. the blood pressure value. CHF is often
preceded by isolated systolic hypertension.
Arterial hypertension has a high prevalence in the group of
older patients with CHF, in whom CHF secondary to arterialhypertension is often associated with preserved left ventricu-
lar systolic function [6]. CHF with preserved left ventricular
systolic function accounts for up to 50% of all cases of HF in
adults older than 65 years. In the Helsinki Ageing Study 72%
subjects with CHF had normal systolic function. Diastolic HF
was found in 51% of patients and arterial hypertension was the
cause of CHF in 54% subjects [7].
Some comorbid conditions contribute to the development
of pluricausal cardiomyopathy: CHD, diabetes mellitus and
alcohol consumption. In the Framingham study, myocardial
infarction, diabetes mellitus, left ventricular hypertrophy and
valvular heart disease were predictive for CHF in both sexes
with arterial hypertension. Mainly association of diabetes
mellitus and arterial hypertension with CHF exceeds that
would be expected from either one alone [8,9].3. The cardiovascular continuum—from
arterial hypertension to chronic heart failure
The CHF syndrome is a consequence of several systemic
responses. In the early stages of arterial hypertension, the left
ventricular structure and function is normal. With time the
pathologic effects of one or more risk factors will reset in the
development of functional and structural changes with left
ventricular hypertrophy (LVH) and myocardial infarction (MI).
This results in the development of diastolic and systolic
dysfunction which leads to heart failure [10].
Arterial hypertension has been identiﬁed as the main
precursor of left ventricular hypertrophy. Subjects with mild
hypertension have two to three-fold higher risk for develop-
ing hypertrophy compared with normotensive subjects. The
development of cardiac hypertrophy is associated with
degenerative changes in cardiac myocytes and an abnormal
accumulation of collagen in the interstitial spaces. These
events cause diastolic dysfunction initially. The presence of
LVH is also an important risk factor for MI. Several observa-
tional studies showed a signiﬁcant, graded and strong rela-
tionship between blood pressure and the incidence of
coronary events [11]. The pathological changes following an
MI are characterized by left ventricular remodeling which is
enhanced in the presence of arterial hypertension.
Asymptomatic systolic and diastolic cardiac dysfunction
may progress to overt heart failure through the compensa-
tory activation of sympathetic nervous system and the renin–
angiotensin–aldosterone system (RAAS).4. Prevention of heart failure in arterial
hypertension
It has been suggested that the treatment of arterial hyperten-
sion may reduce the relative risk of CHF by approximately
50%. The effect of the treatment of arterial hypertension on
the development of CHF was shown in isolated systolic
hypertension, the relative risk was reduced by 51% in the
STOP study and by 55% in the SHEP trial [12]. A meta-analysis
of the efﬁcacy of various antihypertensive therapies, particu-
larly high-doses of diuretics, demonstrated the effect of
reducing the risk of CHF by treating arterial hypertension [13].
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different classes of antihypertensive agents revealed that
for new-onset heart failure, ACE-inhibitors were comparable
and not different to diuretic/beta-blockers-based regimens
[15]. Overall, it is sufﬁcient that inhibitors of RAAS are at least
as effective as diuretic/beta-blocker-based therapy in redu-
cing the incidence of CHF in hypertensive patients. In con-
trast to diuretic/beta-blockers therapy, RAAS inhibitors
including ACE-inhibitors (ACEI) and angiotensin receptor
blockers (ARB) have potential to prevent the development of
new onset diabetes mellitus.5. Treatment of arterial hypertension in
patients with chronic heart failure
Patients with CHF may present with arterial hypertension.
Higher blood pressure is a predictor of better survival in the
hypertensive patients compared to normotensive or hypo-
tensive individuals [16]. Thus, arterial hypertension imposes
an increased afterload in patients with established CHF
which can produce large changes in stroke volume. Several
classes of drugs, including betablockers (BB), ACEI, ARB and
aldosterone antagonists have been shown to improve out-
come in patients with CHF.
The treatment of arterial hypertension in patients with CHF
must take into account the type of cardiac dysfunction: systolic
or diastolic. In systolic dysfunction, the goal of antihypertensive
therapy is to reduce both preload and afterload. The preferred
antihypertensive therapy includes diuretics, aldosterone
antagonists, ACEI and BB, all which have strong evidence of
improving survival in CHF. ACEI are the primary therapy for
heart failure. ACEI in patients with mild to advanced CHF
reduce the rate of progressive cardiac dysfunction and decrease
cardiovascular mortality. They are also effective in subjects
with asymptomatic left ventricular systolic dysfunction in
terms of a lower incidence of overt heart failure. ACEIs have
additional advantage in hypertensive patients with LVH.
The importance of ACEI beneﬁt in subjects with CHF and left
ventricular systolic dysfunction was evident in large rando-
mized clinical trials in the patients post myocardial infarction.
The strongest evidence have among other ACEI: captopril,Table 1 – Dosing of ACEI.
Initial dose (mg) Doses p
Captopril 18.75 3
Enalapril 2.5 2
Lisinopril 2.5 1
Ramipril 2.5 1
Trandolapril 0.5 1
Table 2 – Dosing of ARB.
Initial dose (mg) Doses p
Losartan 12.5 1
Valsartan 40 2
Candesartan 4 1enalapril, ramipril and trandolapril [17–20]. For example, the
treatment with trandolapril in patients with left ventricular
systolic dysfunction soon after myocardial infarction in the
TRACE study reduced the all-cause mortality, cardiovascular
mortality, the risk of the development of the severe heart
failure, the risk of sudden death and the risk of atrial
ﬁbrillation [21].
The follow-up of the TRACE study compared patients with
trandolapril therapy from the original study and subjects, in
whom trandolapril was given after the end of original study.
The twelve years follow-up TRACE study showed better
survival in patients with early treatment with trandolapril.
This result accentuates the need of early ACEI treatment in
subjects with left ventricular systolic dysfunction post MI in
order to increase clinical beneﬁt for the patient.
The effect of ACEI on mortality and morbidity is dose-
dependent [22]. The dose of ACEI should be titrated to
maximal tolerated one. The recommended initial and target
doses of ACEI with evidence of mortality/morbidity reduction
are shown in Table 1.
The drugs with prolonged effect and once daily dosing
should be preferred with respect to patients compliance.
ARB are usually given to patients who are intolerant of
ACEI. The indication for ARB therapy is identical to ACEI in
CHF patients. There is no evidence, that ARB are better than
ACEI. The advantage of ACEI/ARB combination therapy in
CHF was not proved.
For the treatment of CHF, losartan, valsartan and cande-
sartan are approved [23,24].
The recommended initial and target doses of ARB are
shown in the Table 2.
Beta blockers reduce the increased sympatoadrenal activity
on the beta receptors level. According to the results of large
randomized clinical trials betablockers are considered as the
standard therapy in patients with mild to advanced CHF. BB
reduce all cause and cardiovascular mortality, risk of sudden
death, risk of heart failure hospitalization and the risk of death
because of heart failure progression. The best evidence is for
carvedilol, metoprolol succinate, bisoprolol and nebivolol
[25–28]. The effect of BB on outcome is dose dependent too.
The recommended initial and target BB doses are shown in
the Table 3.er day Target dose Doses per day
150 3
20 2
20–35 1
5 2
4 1
er day Target dose Doses per day
50–100 2
160 2
32 1
Table 3 – Dosing of BB.
Carvedilol Metoprolol succinate Bisoprolol Nebivolol
Initial dose (mg) 3.125 bid 12.5 od 1.25 od 2.5 od
Target dose (mg) 25–50 bid 150–200 od 10 od 10 od
Table 4 – Recommended doses of diuretics in CHF.
Initial dose Usual daily dose
Loop diuretic
Furosemid 20–40 40–240 (250 mg)
Thiazid diuretic
hydrochlorothiazid 25 12.5–100
indapamid 2.5 2.5–5
Potassium sparing diuretic Usual In absence of ACEI/ARB Usual In absence of ACEI/ARB
Amilorid 2.5 5 5–10 10–20
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chronic heart failure NYHA II–IV in order to decrease mortal-
ity and the risk of hospitalization for heart failure [29,30].
Loop and thiazide diuretics are effective in subjects with
ﬂuid overload. Loop diuretics can be used in hypertension
crisis in acute heart failure patients and in the severe
hypertension in chronic heart failure, mainly in individuals
with impaired kidney function [31]. Recommended diuretics
doses are shown in the Table 4.
If the blood pressure in heart failure patients remains high
despite the optimal heart failure therapy, vasodilators as the
combination of hydralazine and isosorbide dinitrate, or dihy-
dropyridine calcium channel blockers (CCB) can be used [32].
The treatment of hypertensive subjects with diastolic
cardiac dysfunction and CHF is uncertain. The role of RAAS
inhibition is less clear. Excessive preload reduction in dia-
stolic dysfunction should be avoided, this can lead to drop in
cardiac output and hypotension. Diuretics, venodilators and
dihydropyridine CCB should be use with caution in diastolic
heart failure.
LVH is usually present in diastolic heart failure. Regression
of LVH is an important therapeutical goal. The relative
reductions in left ventricular mass were shown after the
treatment with ARB, CCB, and ACEI, which all produced
signiﬁcantly more regression than betablockers [33]. In con-
trast to systolic heart failure, verapamil (non-dihydropyridine
CCB) may be beneﬁcial in this setting [34].6. Conclusion
Arterial hypertension is leading cause of left ventricular
hypertrophy and subsequent development of CHF.
The optimal target blood pressure for patients with CHF is
not deﬁned.
In the subjects with systolic dysfunction, the goal of
therapy is the lowest blood pressure that is not associated
with symptoms of hypotension or hypoperfusion.In patients with diastolic heart failure, achievable blood
pressure varies widely from patient to patient because of risk
of excessive preload and afterload reduction with intensive
antihypertensive regimens.
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